{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:06:28Z","timestamp":1792076788936,"version":"4.4.0"},"reference-count":53,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["159507"],"award-info":[{"award-number":["159507"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Remdesivir (GS-5734) is a 1\u2032-cyano-substituted adenosine nucleotide analogue prodrug that shows broad-spectrum antiviral activity against several RNA viruses. This compound is currently under clinical development for the treatment of Ebola virus disease (EVD). While antiviral effects have been demonstrated in cell culture and in non-human primates, the mechanism of action of Ebola virus (EBOV) inhibition for remdesivir remains to be fully elucidated. The EBOV RNA-dependent RNA polymerase (RdRp) complex was recently expressed and purified, enabling biochemical studies with the relevant triphosphate (TP) form of remdesivir and its presumptive target. In this study, we confirmed that remdesivir-TP is able to compete for incorporation with adenosine triphosphate (ATP). Enzyme kinetics revealed that EBOV RdRp and respiratory syncytial virus (RSV) RdRp incorporate ATP and remdesivir-TP with similar efficiencies. The selectivity of ATP against remdesivir-TP is ~4 for EBOV RdRp and ~3 for RSV RdRp. In contrast, purified human mitochondrial RNA polymerase (h-mtRNAP) effectively discriminates against remdesivir-TP with a selectivity value of ~500-fold. For EBOV RdRp, the incorporated inhibitor at position i does not affect the ensuing nucleotide incorporation event at position i+1. For RSV RdRp, we measured a ~6-fold inhibition at position i+1 although RNA synthesis was not terminated. Chain termination was in both cases delayed and was seen predominantly at position i+5. This pattern is specific to remdesivir-TP and its 1\u2032-cyano modification. Compounds with modifications at the 2\u2032-position show different patterns of inhibition. While 2\u2032-C-methyl-ATP is not incorporated, ara-ATP acts as a non-obligate chain terminator and prevents nucleotide incorporation at position i+1. Taken together, our biochemical data indicate that the major contribution to EBOV RNA synthesis inhibition by remdesivir can be ascribed to delayed chain termination. The long distance of five residues between the incorporated nucleotide analogue and its inhibitory effect warrant further investigation.<\/jats:p>","DOI":"10.3390\/v11040326","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T11:31:57Z","timestamp":1554377517000},"page":"326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":532,"title":["Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir"],"prefix":"10.3390","volume":"11","author":[{"given":"Egor P.","family":"Tchesnokov","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada"},{"name":"Li Ka Shing Institute of Virology at University of Alberta, Edmonton, AB T6G 2E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Y.","family":"Feng","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle P.","family":"Porter","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"G\u00f6tte","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada"},{"name":"Li Ka Shing Institute of Virology at University of Alberta, Edmonton, AB T6G 2E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"ref_1","unstructured":"WHO (2019, March 12). List of Blueprint Priority Diseases. Available online: http:\/\/www.who.int\/blueprint\/priority-diseases\/en\/."},{"key":"ref_2","unstructured":"CDC (2019, March 12). 2014\u20132016 Ebola Outbreak in West Africa, Available online: https:\/\/www.cdc.gov\/vhf\/ebola\/history\/2014-2016-outbreak\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Longini","year":"2015","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1128\/JVI.01490-15","article-title":"Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies","volume":"89","author":"Davidson","year":"2015","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection","volume":"375","author":"Group","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kimble, J.B., Malherbe, D.C., Meyer, M., Gunn, B.M., Karim, M.M., Ilinykh, P.A., Iampietro, M., Mohamed, K.S., Negi, S., and Gilchuk, P. (2018). Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza-Vectored Ebolavirus Vaccine. J. Virol.","DOI":"10.1128\/JVI.01845-18"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., Smith, E.C., Case, J.B., Feng, J.Y., and Jordan, R. (2018). Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio, 9.","DOI":"10.1128\/mBio.00221-18"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40506-016-0085-5","article-title":"Japanese Surveillance Systems and Treatment for Influenza","volume":"8","author":"Zaraket","year":"2016","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., and Deval, J. (2013). The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068347"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Guedj, J., Piorkowski, G., Jacquot, F., Madelain, V., Nguyen, T.H.T., Rodallec, A., Gunther, S., Carbonnelle, C., Mentr\u00e9, F., and Raoul, H. (2018). Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002535"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., and Danel, C. (2016). Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","article-title":"Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides","volume":"15","author":"Witkowski","year":"1972","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antiviral Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antiviral Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jordan, P.C., Liu, C., Raynaud, P., Lo, M.K., Spiropoulou, C.F., Symons, J.A., Beigelman, L., and Deval, J. (2018). Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006889"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.virusres.2017.01.008","article-title":"Polymerases of paramyxoviruses and pneumoviruses","volume":"234","author":"Fearns","year":"2017","journal-title":"Virus Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41598-018-22328-3","article-title":"Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus","volume":"8","author":"Tchesnokov","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Noton, S.L., Deflube, L.R., Tremaglio, C.Z., and Fearns, R. (2012). The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002980"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Deval, J., Hong, J., Wang, G., Taylor, J., Smith, L.K., Fung, A., Stevens, S.K., Liu, H., Jin, Z., and Dyatkina, N. (2015). Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2\u2032-Fluoro-4\u2032-Chloromethyl-Cytidine Triphosphate. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004995"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14628","DOI":"10.1073\/pnas.1209147109","article-title":"Critical phosphoprotein elements that regulate polymerase architecture and function in vesicular stomatitis virus","volume":"109","author":"Rahmeh","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/JVI.73.3.2333-2342.1999","article-title":"Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems","volume":"73","author":"Muhlberger","year":"1999","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1021\/bi200350d","article-title":"Human mitochondrial RNA polymerase: evaluation of the single-nucleotide-addition cycle on synthetic RNA\/DNA scaffolds","volume":"50","author":"Smidansky","year":"2011","journal-title":"Biochemistry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/nbt1036","article-title":"Baculovirus expression system for heterologous multiprotein complexes","volume":"22","author":"Berger","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/0471140864.ps0520s51","article-title":"MultiBac: Multigene baculovirus-based eukaryotic protein complex production","volume":"51","author":"Bieniossek","year":"2008","journal-title":"Curr. Protoc. Protein Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1074\/jbc.M210914200","article-title":"Inhibition of hepatitis C virus RNA replication by 2\u2032-modified nucleoside analogs","volume":"278","author":"Carroll","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1128\/AAC.02666-14","article-title":"Efficiency of incorporation and chain termination determines the inhibition potency of 2\u2032-modified nucleotide analogs against hepatitis C virus polymerase","volume":"58","author":"Fung","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.08.004","article-title":"Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus","volume":"9","author":"Deval","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.antiviral.2014.03.018","article-title":"High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses","volume":"106","author":"Uebelhoer","year":"2014","journal-title":"Antiviral Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","article-title":"Discovering Drugs for the Treatment of Ebola Virus","volume":"9","author":"Bixler","year":"2017","journal-title":"Curr Treat. Options Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2017.04.005","article-title":"Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs","volume":"143","author":"Jin","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1128\/AAC.01391-15","article-title":"Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2\u2032-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases","volume":"59","author":"Jin","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"34218","DOI":"10.1074\/jbc.M806797200","article-title":"Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase","volume":"283","author":"Tchesnokov","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1074\/jbc.M707834200","article-title":"Pre-steady-state kinetic studies establish entecavir 5\u2032-triphosphate as a substrate for HIV-1 reverse transcriptase","volume":"283","author":"Domaoal","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1128\/AAC.42.12.3200","article-title":"In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir","volume":"42","author":"Seifer","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.41.7.1444","article-title":"Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus","volume":"41","author":"Innaimo","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir\u2014effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N Engl. J. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/4\/326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:57Z","timestamp":1760186577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/4\/326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["v11040326"],"URL":"https:\/\/doi.org\/10.3390\/v11040326","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]}}}